The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy

Shangbo Lei; Jiamin Jin; Xiangfeng Zhao; Lihua Zhou; Guangying Qi; Jinfeng Yang

doi:10.1177/15353702221102094

The role of IL-33/ST2 signaling in the tumor microenvironment and Treg immunotherapy

Exp Biol Med (Maywood). 2022 Oct;247(20):1810-1818. doi: 10.1177/15353702221102094. Epub 2022 Jun 22.

Authors

Shangbo Lei^{1

2

3}, Jiamin Jin³, Xiangfeng Zhao¹, Lihua Zhou³, Guangying Qi^{2

3}, Jinfeng Yang^{1

3}

Affiliations

¹ Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China.
² Department of Pathophysiology, Guilin Medical University, Guilin 541199, Guangxi, China.
³ Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, Guangxi, China.

Abstract

Interleukin (IL)-33 is a tissue-derived nuclear cytokine belonging to the IL-1 family. Stimulation-2 (ST2) is the only known IL-33 receptor. ST2 signals mostly on immune cells found within tissues, such as regulatory T cells (Treg cells), CD8+ T cells, and natural killer (NK) cells. Therefore, the IL-33/ST2 signaling pathway is important in the immune system. IL-33 deficiency impairs Treg cell function. ST2 signaling is also increased in active Treg cells, providing a new approach for Treg-related immunotherapy. The IL-33/ST2 signaling pathway regulates multiple immune-related cells by activating various intracellular kinases and factors in the tumor microenvironment (TME). Here, we review the latest studies on the role of the IL-33/ST2 signaling pathway in TME and Treg immunotherapy.

Keywords: Biology; cancer; interleukin-33; regulatory T cell; stimulation-2; tumor microenvironment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Immunotherapy
Interleukin-1 Receptor-Like 1 Protein*
Interleukin-33
T-Lymphocytes, Regulatory*
Tumor Microenvironment

Substances

Interleukin-1 Receptor-Like 1 Protein
Interleukin-33